AEON Biopharma, Inc. (AEON)
ASE · Healthcare · Biotechnology
$0.33
+12.72%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$16.3M
Shares Outstanding
49.9M
Exchange
ASE
Currency
USD
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (2.5M) | (5.5M) | (5.9M) | (5.9M) |
| Net Income | (4.5M) | (37.1M) | (11.8M) | (1.2M) |
| Diluted EPS | $-0.39 | N/A | $-0.29 | $-0.02 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | |
| Operating Income | (48.4M) | (27.8M) | (16.3M) | |
| Net Income | (52.6M) | 42.0M | (39.2M) | |
| Diluted EPS | $-172.03 | N/A | $72.93 | $-3.95 |